Global Rheumatic Disorders Drugs Market to 2024 – Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

– How is the rheumatic disorders landscape expected to change?

– Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?

– Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?

– Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?

– The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?

– What types of companies are involved in the rheumatic disorder therapy area?

– Will the current market leaders retain their dominance over the forecast period?

– How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications

- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market

- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates

- Identify which two drug classes will see particularly strong market growth over the forecast period

- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion

- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 12

2.1 Therapy Area Overview 12

2.1.1 Rheumatoid Arthritis 12

2.1.2 Osteoarthritis 13

2.1.3 Osteoporosis 14

2.1.4 Systemic Lupus Erythematosus 15

2.1.5 Psoriatic Arthritis 16

2.2 Etiology 17

2.3 Pathophysiology 19

2.3.1 Rheumatoid Arthritis 19

2.3.2 Osteoarthritis 20

2.3.3 Osteoporosis 20

2.3.4 Systemic Lupus Erythematosus 21

2.3.5 Psoriatic Arthritis 22

2.4 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 23

2.4.1 Rheumatoid Arthritis 24

2.4.2 Osteoarthritis 25

2.4.3 Osteoporosis 26

2.4.4 Systemic Lupus Erythematosus 27

2.4.5 Psoriatic arthritis 28

2.5 Treatment 29

2.5.1 Rheumatoid Arthritis 29

2.5.2 Osteoarthritis 31

2.5.3 Osteoporosis 32

2.5.4 Systemic Lupus Erythematosus 35

2.5.5 Psoriatic Arthritis 37

3 Key Marketed Products 40

3.1 Overview 40

3.2 Humira (adalimumab) - AbbVie 41

3.3 Enbrel (etanercept) - Amgen 44

3.4 Simponi (golimumab) - Johnson & Johnson 46

3.5 Remicade (infliximab) - Johnson & Johnson 48

3.6 Rituxan (rituximab) - Roche 51

3.7 Stelara (ustekinumab) - Johnson & Johnson 52

3.8 Cosentyx (secukinumab) - Novartis 54

3.9 Prolia (denosumab) - Amgen 55

3.10 Orencia (abatacept) - Bristol-Myers Squibb 57

3.11 Actemra (tocilizumab) - Roche 59

3.12 Benlysta (belimumab) - GlaxoSmithKline 60

3.13 Forteo (teriparatide) - Eli Lilly 62

4 Pipeline Landscape Assessment 64

4.1 Overview 64

4.2 Pipeline Development Landscape 64

4.3 Molecule Types in the Pipeline 67

4.4 Molecular Targets in the Pipeline 68

4.5 Clinical Trials Landscape 70

4.5.1 Clinical Trial Failure Rates 70

4.5.2 Clinical Trial Duration 73

4.5.3 Clinical Trial Size 77

4.5.4 Cumulative Clinical Program Size 81

4.6 Assessment of Key Pipeline Products 85

4.6.1 Upadacitinib tartrate - AbbVie 85

4.6.2 Filgotinib - Gilead Sciences 86

4.6.3 Lenabasum - Corbus Pharmaceuticals 88

4.6.4 Evenity (romosozumab) - Amgen / UCB / Astellas 89

4.6.5 Avacopan - ChemoCentryx 90

4.6.6 Pegadricase - Selecta Biosciences 92

4.6.7 Anifrolumab - AstraZeneca 94

5 Multi-scenario Market Forecast to 2024 96

5.1 Overall Market Size 96

5.2 Generic Penetration 99

5.3 Revenue Forecast by Molecular Target 101

5.3.1 Products Acting on Tumor Necrosis Factor-Alpha 101

5.3.2 Products Acting on Interleukins and Interleukin Receptors 102

5.3.3 Products Acting on Protein Kinases 103

5.3.4 Products Acting on Cell Surface Antigens 104

5.3.5 Products Acting on Hormones and Hormone Receptors 105

6 Company Analysis and Positioning 107

6.1 Revenue and Market Share Analysis by Company 109

6.1.1 AbbVie 117

6.1.2 Amgen 118

6.1.3 Johnson & Johnson 119

6.1.4 Novartis 120

6.1.5 Pfizer 122

6.1.6 Roche 124

6.1.7 Eli Lilly 125

6.1.8 Bristol-Myers Squibb 126

6.2 Company Landscape 127

6.3 Marketed and Pipeline Portfolio Analysis 129

7 Strategic Consolidations 131

7.1 Licensing Deals 131

7.1.1 Deals by Region, Year and Value 131

7.1.2 Deals by Indication and Value 133

7.1.3 Deals by Stage of Development and Value 134

7.1.4 Deals by Molecule Type, Molecular Target and Value 135

7.1.5 Licensing Deals with Disclosed Values 136

7.2 Co-development Deals 142

7.2.1 Deals by Region, Year and Value 142

7.2.2 Deals by Indication and Value 143

7.2.3 Deals by Stage of Development and Value 144

7.2.4 Deals by Molecule Type, Molecular Target and Value 145

7.2.5 Co-development Deals with Disclosed Values 146

8 Appendix 149

8.1 References 149

8.2 Figures of All Clinical Stage Pipeline Products 162

8.3 Abbreviations 176

8.4 Disease List 177

8.5 Methodology 177

8.5.1 Coverage 178

8.5.2 Secondary Research 178

8.5.3 Market Size and Revenue Forecasts 178

8.5.4 Pipeline Analysis 179

8.5.5 Competitive Landscape 179

8.6 Contact Us 179

8.7 Disclaimer 180

List of Tables

1.1 List of Tables

Table 1: Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018 17

Table 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018 23

Table 3: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018 30

Table 4: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018 31

Table 5: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018 32

Table 6: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018 32

Table 7: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018 34

Table 8: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018 34

Table 9: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018 36

Table 10: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018 37

Table 11: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018 38

Table 12: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018 39

Table 13:Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018 40

Table 14: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018 41

Table 15: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018 44

Table 16: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018 46

Table 17: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018 48

Table 18: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018 51

Table 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018 52

Table 20: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018 54

Table 21: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018 55

Table 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018 57

Table 23: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018 59

Table 24: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018 60

Table 25: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018 62

Table 26: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 97

Table 27: Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018 100

Table 28: Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017-2024 109

List of Figures

1.2 List of Figures

Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017-2024 24

Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017-2024 25

Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017-2022 26

Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017-2024 27

Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017-2024 28

Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006-2024 43

Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2024 45

Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2024 47

Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2024 50

Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 52

Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010-2024 53

Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2024 55

Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010-2024 56

Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014-2023 58

Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016-2024 60

Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011-2024 61

Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006-2024 63

Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 64

Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018 65

Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018 66

Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018 67

Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018 68

Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018 69

Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006-2018 70

Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2018 71

Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2018 72

Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2018 73

Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 73

Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2018 74

Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2018 75

Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2018 76

Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 77

Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2018 78

Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2018 79

Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2018 80

Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 81

Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2018 82

Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2018 83

Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2018 84

Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019-2024 86

Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019-2024 87

Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021-2024 88

Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019-2024 90

Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021-2024 92

Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020-2024 93

Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019-2024 95

Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017-2024 96

Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 99

Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-α ($bn), 2017-2024 102

Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017-2024 103

Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017-2024 104

Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017-2024 105

Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017-2024 106

Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017-2024 107

Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017-2024 108

Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024 113

Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 115

Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017-2024 116

Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017-2024 118

Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017-2024 119

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports